2Misra J S, Srivastava S, Singh U, et al. Risk factors and strat2egies for control of carcinoma cervix in India: Hospital basedcytological screening experience of 35 years [J]. Indian Jcancer,2009,46 (2) :155-159.
8Munoz N , Bosch FX , Sanjose SD et al. Epidemiologic classification of human papillomavims types associated with cervical cancer [ J] . N En- gl J Med, 2003, 348 (6): 518.
9Cihas ES, Zou KH, Crum CP et al. Using the rate of positive high - risk HPV test results for ASC - US together with the ASC - US/SIL ratio in evaluation the performance of cytopathologists [J]. Am J Clin Pathol, 2008, 129 (1): 97.
10Apgar BS, Brotzman G. HPV testing in the evaluation of the minimally abnormal papanicolaou smear [ J] . AM Fam Physician, 1999, 59 ( 10 ) : 2794.
3Kara M, Tatar A, Borekci B, et al. Mitochondrial DNA 4977 bp deletion in chronic cervicitis and cervix cancers EJ]. Balkan J Med Genet,2012,15 ( 1 ):25-29.
4Changani L, Bouzari M, Talebi A, et al. Torque teno mini virus infection in chronic cervicitis and cervical tumors in Isfahan, Iran [J]. Intervirology,2013,56 ( 4 ):265-270.
5Bis RL, Stauffer TM, Singh SM, et al. High yield soluble bacterial expression and streamlined purification of recombinant human interferon ct-2a[J ]. Protein Expr Purif,2014,99:138-146.
6Gull I, Samra ZQ, Aslam MS, et al. Heterologous expression, immuno- chemical and computational analysis of recombinant human interferon alpha 2b[J]. Springerplus,2013,2 ( 1 ):1-8.
